肺癌患者术前辅助化疗与肺部感染的相关性研究  

Correlation of preoperative adjuvant chemotherapy and lung infection in lung cancer patients

作　　者：钱继杭[1] 侯宪红 吴新国[1] 

机构地区：[1]泰安市肿瘤防治院外科,山东泰安271000 [2]泰安市肿瘤防治院护理部,山东泰安271000

出　　处：《中华医院感染学杂志》2015年第3期644-646,共3页Chinese Journal of Nosocomiology

基　　金：山东省泰安市科技发展计划基金资助项目(20132112)

摘　　要：目的探讨肺癌术前辅助化疗与肺部感染的关系,为提高肺癌的治愈率和患者生存率提供研究依据。方法选取2008年1月-2010年12月进行肺癌手术的126例患者为研究对象,所有患者随机分为两组,各63例,肺癌术前辅助化疗患者设为试验组,单纯肺癌手术患者设为对照组,采用不同方式化疗后,分别对两组肺癌患者手术后的肺部感染及临床治疗效果进行分析,数据采用SPSS15.0软件进行统计处理。结果单纯肺癌手术对照组的63例患者,术后肺部感染为58.7%,试验组63例患者,术后肺部感染为38.1%,术前辅助化疗后,试验组的肺部感染明显低于手术对照组,差异有统计学意义(P<0.05);对照组术后完全缓解占19.0%、部分缓解36.5%、总有效率55.6%,试验组63术后完全缓解占30.2%、部分缓解49.2%、总有效率79.4%,试验组的治疗效果明显高于对照组,差异有统计学意义(P<0.05);术后1年存活率对照组为81.0%、试验组为88.9%,不同方式治疗后,两组患者1年生存率基本相同,差异无统计学意义。结论肺癌术前辅助化疗可显著降低肺部感染率,提高手术后疗效以及患者的3年生存率。OBJECTIVE To investigate the relationship of adjuvant chemotherapy for lung cancer and postoperative lung infection, in order to provide research basis for improvement of the cure rate and survival rate of lung cancer patients. METHODS Totally 126 patients undergoing lung cancer surgery during Jan. 2008 - Dec. 2010 were enrolled in the study, all patients were randomly divided into two groups with 63 patients in each group. The patients who received preoperative adjuvant chemotherapy were set as the test group, and those who received single lung cancer surgery as the control group. Lung infection and clinical outcomes of two groups of patients with lung cancer were observed after performance of different approaches of chemotherapy. Data were analyzed statistically with the software SPSS15.0. RESULTS The postoperative lung infection rate was 58. 7% in the control group and 38.1% in the test group. The ineidence of postoperative lung infeetion was significantly lower in the test group than in the control after chemotherapy （P〈0.05）. In the control group, 19.0% of the patients had complete remission, 36.5% had partial remission, with the total efficiency of 55.6 %. In the test group, 30.2% of the patients had complete remission, 49. 2% had partial remission, with the total efficiency of 79. 4%, indicating the treatment efficacy was significantly higher in the test group than in the control group （P〈0.05）. The one year survival rate after surgery was 81.0% in the control group and 88.9% in the test group, indicating that the one year survival rate was generally the same in the two groups after treatment in different ways, the difference was not significant. CONCLUSION Adjuvant chemotherapy before lung cancer surgery can significantly reduce lung infection and improve the efficacy of surgery and the 3-year survival rate of patients.

关 键 词：肺癌 术前辅助化疗 肺部感染 相关性研究 

分 类 号：R619.3[医药卫生—外科学]